BRISTOL MYERS SQUIBB CO
Company Stats
- Market Cap
- $127.5B
- as of Sep 30, 2026
- Shares Outstanding
- 2.0B
- Free Float
- 99.9%
Income Statement
- Revenue
- $48.2B
- Net Income
- $7.1B
- Revenue Growth, 3Y
- 1.4%
- FCF Margin, 3Y Avg
- 27.9%
- FCF Margin, Worst Year
- 26.7%
Cash Flow
- Free Cash Flow
- $12.8B
- FCF Yield
- 10.1%
- Owner FCF Yield
- 9.6%
Balance Sheet
- Cash & Equivalents
- $10.2B
Returns & Capital
- Dividends Paid
- $5.0B
- Dividend Yield
- 4.0%
- Buyback Yield, 3Y Avg
- 1.3%
- SBC, 3Y Avg
- $526.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $48.2B | $12.8B | 26.7% |
| FY2024 | $48.3B | $13.9B | 28.9% |
| FY2023 | $45.0B | $12.7B | 28.1% |
| FY2022 | $46.2B | $11.9B | 25.9% |
| FY2021 | $46.4B | $15.2B | 32.8% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 6, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
November 4, 2026
Peer Earnings Note
Bristol Myers and AbbVie Take Different Paths to Fund Growth
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 24, 2026
FDA
FDA Approves Bristol Myers Squibb's Zenbexus
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
Bristol Myers and AbbVie Take Different Paths to Fund Growth
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 24, 2026
FDA
FDA Approves Bristol Myers Squibb's Zenbexus
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back